Invention Grant
- Patent Title: Bispecific HER2 ligands for cancer therapy
-
Application No.: US14430224Application Date: 2013-10-14
-
Publication No.: US10093740B2Publication Date: 2018-10-09
- Inventor: Rastislav Tamaskovic , Martin Schwill , Andreas Pluckthun , Christian Jost
- Applicant: UNIVERSITAT ZURICH
- Applicant Address: CH Zurich
- Assignee: Universitat Zurich
- Current Assignee: Universitat Zurich
- Current Assignee Address: CH Zurich
- Agency: JMB Davis Ben-David
- Priority: EP12188598 20121015; EP12191673 20121107; EP12192465 20121113; EP13185724 20130924
- International Application: PCT/EP2013/071443 WO 20131014
- International Announcement: WO2014/060365 WO 20140424
- Main IPC: C07K16/46
- IPC: C07K16/46 ; A61K39/395 ; C07K16/28 ; C07K16/32
Abstract:
The invention relates to a bispecific HER2-targeting agent comprising a.) a first polypeptide ligand that binds to HER2 extracellular domain 1, b.) a second polypeptide ligand that binds to HER2 extracellular domain 4 and c.) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.
Public/Granted literature
- US20150284463A1 BISPECIFIC HER2 LIGANDS FOR CANCER THERAPY Public/Granted day:2015-10-08
Information query
